Hims & Hers Health (HIMS)·Q4 2025 Earnings Summary
Hims & Hers Beats on EPS, Guides to $2.9B Revenue as GLP-1 Uncertainty Looms
February 23, 2026 · by Fintool AI Agent
Hims & Hers delivered Q4 2025 results that beat on profitability while revenue came in essentially flat to expectations. The telehealth leader reported revenue of $618M (+28% YoY), diluted EPS of $0.08 (vs $0.04 consensus), and Adjusted EBITDA of $66M (+23% YoY) . Despite the beat, shares traded down ~1% in after-hours amid 33.7% short interest and ongoing regulatory scrutiny around compounded GLP-1 products .
Did Hims & Hers Beat Earnings?
The company delivered mixed results against a cautious consensus:
The EPS beat was driven by better-than-feared operating leverage despite gross margin compression. Gross margin declined 500 bps YoY primarily due to: (1) growing international contributions with lower margins, (2) new specialty launches, and (3) shorter shipping cadences in weight loss .
Full year 2025 results showed the platform's strength: revenue grew 59% to $2.35B with Adjusted EBITDA of $318M (+80% YoY) .
Ask Fintool AI AgentWhat Did Management Guide?
Management provided FY 2026 guidance that implies continued growth, albeit at a slower pace:
Key assumptions in guidance :
- Excludes Eucalyptus acquisition (expected to close mid-2026)
- Assumes ongoing ability to provide compounded semaglutide
- No changes to current business relationships
The Q1 guidance implies a sequential revenue decline of ~2% at midpoint, which management attributed to investment timing rather than demand weakness. FY 2026 revenue at the midpoint ($2.8B) represents 19% growth, a significant deceleration from 59% in 2025.
How Did the Stock React?
HIMS shares closed at $15.55 before the after-hours release and traded down to $15.38 (-1.1%) in extended trading. The muted reaction comes after a brutal decline from the 52-week high of $70.43, with shares down 78% from peak levels.
Key context for the stock:
- Short interest: 33.7% (record high heading into earnings)
- 50-day MA: $29.39 (stock 47% below)
- 200-day MA: $45.04 (stock 66% below)
- Analyst price target: $27.46 avg (+76% upside)
The elevated short interest creates potential for volatility in either direction depending on how the market interprets the guidance and GLP-1 regulatory outlook.
What Changed From Last Quarter?
Several notable shifts emerged this quarter:
1. International Expansion Accelerating
- Rest of World revenue grew 399% YoY to $134M in 2025
- Q4 alone saw ROW revenue of $64M vs $7M in Q4 2024 (+825% YoY)
- Eucalyptus acquisition announced (>$450M ARR, closing H2 2026) with up to $1.15B total consideration
- International business expected to breakeven within 12-18 months (including Eucalyptus)
- Management targets $1B+ international revenue within 3 years
2. New Specialties Launched
- Hormone therapies: Testosterone support, menopause, perimenopause
- Labs by Hims & Hers: 130+ biomarkers for preventative care
-
95% of testosterone customers saw increased levels after 2 months
3. Profitability Investments
- Capital expenditures reached $226M in FY 2025 (vs $42M in FY 2024)
- Free cash flow dropped to $57M from $198M due to facility buildout
- Over $300M deployed in capex over last 3 years for 1M+ sq ft of facilities
4. Capital Allocation
- $80M in share repurchases during Q4
- $225M remaining on buyback authorization
- $929M in liquidity (cash + investments)
- ~$1B convertible debt on balance sheet
Ask Fintool AI AgentKey Management Quotes
On platform strength:
"More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we're well on our way to becoming the global leader in consumer health." — Andrew Dudum, CEO
On GLP-1 diversification:
"The majority of our revenue in 2025 came from non-GLP-1 offerings. We expect these businesses to continue growing in 2026, and we've never been better positioned to scale new markets and new specialties."
On personalized care:
"At the end of 2025, more than 1.6 million subscribers were utilizing a personalized solution, growing more than 30% year-over-year."
On 2030 vision:
"Our success gives us confidence that 2026 is the right moment to invest more, extend our leadership position, and drive toward our 2030 financial ambitions of driving at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA."
Segment Performance
Management noted that Weight Loss, Men's Dermatology, Sexual Health, and Women's Dermatology each now exceed $100M in annual revenue, demonstrating the platform's ability to scale multiple specialties simultaneously .
Q&A Highlights
On GLP-1 Pipeline and Branded Partnerships:
"When you look at both the next generation therapies that the major drug companies are bringing to market, when you look at the pipeline of biotech in phase II and phase III, we deeply believe that in the next 2 to 3 years, there's going to be 12 or maybe 24 added treatments that are going to make a big difference in people's lives." — Andrew Dudum
On Regulatory Engagement: When asked about FDA and DOJ scrutiny, Dudum noted they "continue to welcome their conversations" and believe the FDA "plays an important role in the safety of consumers." He declined to provide specifics on ongoing matters but indicated active engagement with regulators .
On The Oral GLP-1 "Pill" Product: The company pulled back its oral GLP-1 offering after launch: "We pulled it back to prioritize, honestly, just engagement and the relationships with the ecosystem stakeholders. We talked to quite a few of them on launch, understood their dynamics, and chose to prioritize them in those conversations."
On Non-GLP-1 Business Strength:
"Even before we had the compounded GLP-1 business line, our weight loss offerings was the fastest category to ever launch. Just with our combinations of therapies focused on conditions around metabolic and insulin-resistant dynamics. That business scaled to a $100 million run rate in just 7 months." — Andrew Dudum
On AI and Proactive Care Flywheel: Management highlighted early AI deployments: "Early deployments of proactive messaging in weight loss have already driven more than a 50% increase in weight logging frequency, signaling an ability to improve customer commitment and engagement."
On Labs Conversion:
"70% of people who do a lab test on the Hims & Hers platform identify an area of risk that is treatable on the Hims & Hers platform. Most of the time, this is something patients are learning for the first time, that they're pre-diabetic, that they're at risk of cardiovascular disease." — Andrew Dudum
On Guidance Range Swing Factors (CFO Yemi Okupe): The wide guidance range provides flexibility to: (1) lean into new specialties hitting unit economic milestones, (2) accelerate technology/AI investments showing ROI, and (3) invest in international markets including Eucalyptus integration .
Key Operating Metrics
Risk Factors Flagged
1. GLP-1 Regulatory Uncertainty Guidance explicitly assumes "ongoing ability to provide access to compounded semaglutide through our platform" . The company faces litigation from Novo Nordisk and FDA scrutiny on compounded weight-loss products . Management noted they pulled back the oral GLP-1 "pill" product to prioritize relationships with ecosystem stakeholders .
2. Q1 Revenue Timing Headwind Management expects an approximately $65M revenue headwind in Q1 from the change in shipping cadences following the shift to 503A fulfillment (vs ~$40M in H2 2025). "These dynamics affect only the timing of revenue recognition and not customer demand or engagement" .
3. Margin Pressure Gross margin declined 500 bps YoY due to international mix shift and new specialty launches. EBITDA margin guidance of 11-13% for FY 2026 is below the 14% achieved in FY 2025 . Super Bowl commercial investment creates additional Q1 EBITDA pressure .
4. Elevated Short Interest At 33.7%, short interest is at record levels, suggesting significant investor skepticism about the GLP-1 business sustainability .
5. Acquisition Integration Eucalyptus deal totals up to $1.15B consideration (~$240M upfront at close, remainder through 2029) . Multiple acquisitions require execution. G&A expenses increased due to integration and leadership hires .
Forward Catalysts
Ask Fintool AI AgentBottom Line
Hims & Hers delivered a Q4 beat on profitability metrics while managing expectations on revenue. The company's ability to grow non-GLP-1 revenue and expand internationally provides some diversification, but the elephant in the room remains regulatory risk around compounded weight-loss drugs. With short interest at record levels and the stock down 78% from highs, the setup is binary: either the GLP-1 thesis breaks and shorts are vindicated, or regulatory clarity emerges and the squeeze begins.
The 2030 targets of $6.5B revenue and $1.3B EBITDA imply 23% and 32% CAGRs respectively – ambitious but achievable if the platform model continues to scale. Investors will be watching Q1 guidance closely for signs of GLP-1 demand resilience.
Related: